Glutathione S-transferases (GST, EC 2.5.1.18) are a family of phase II detoxification enzymes involved in the conjugation of glutathione to a highly diverse group of compounds. The purpose of this study was to evaluate the dose-response effects of lead acetate administration on the expression of rat kidney GST. Sprague-Dawley rats were injected with doses of lead acetate ranging from 0.11 to 114 mg/kg (0.3 to 300 ftmolfkg) for three consecutive days and sacrificed 24 h later. Kidney GST activity, GST isoform HPLC profiles, blood lead analysis, and electron microscopy were performed. A dose of 1.1 mg/kg lead acetate resulted in a blood lead level of 26 fig/dl and produced a significant increase in GST activity which continued to increase with dose up to 38 mg/kg. Morphological changes were detected at 3.8 mg/kg and increasing severity of cellular damage paralleled dose, blood lead levels, and changes in body weight. Individual GST isoforms exhibited different thresholds and maxima; rGSTPl and rGSTMl had thresholds of 1.1 and 3.8 mg/kg, respectively, very similar rates of increase with dose, and a maximum yield that was 450% above control at a dose of 38 mg/kg for both enzymes. rGSTAl and rGSTA3 showed similar thresholds (1.1 mg/kg) and maximal fold increase (275%) but varied in the relative response to each dose. These results indicate that renal GST increases occur at lead levels which are environmentally significant, that these changes precede cellular damage, and suggest that GST may serve as a tissue biomarker Of lead exposure.
1 To whom correspondence should be addressed at Molecular and Genetic Science Unit, Waisman Center, University of Wisconsin, 1500 Highland Ave., Madison, substrate specificity whereas a trimeric GST has been identified in microsomes (Snyder and Maddison, 1997; Rowe et al, 1998) . GSTs are induced in a tissue-specific manner by a large number of compounds including barbiturates, reactive oxygen species, chemoprotectants (Pickett et al, 1984; Simplicio et al, 1989; McLellan and Hayes, 1989; Derbel et al, 1993) , and lead (Columbano et al, 1983; Suzuki et al, 1996; Daggett et al, 1997) . The isoform-and tissue-specific expression and/or induction of this family of enzymes has been demonstrated to act as an adaptive response and to provide protection against a multitude of dissimilar toxic insults (Hayes and Pulford, 1995) , hepatitis B surface antigen (Fernandes et al, 1996) , aflatoxin B, (McLellan et al, 1994) , and radiation (Kim et al, 1997) .
Exposure to lead is toxic to the hematopoietic and nervous systems, to bone, and to kidney (Nolan and Shaikh, 1992) . High levels of lead accumulate in the kidney where leadinduced pathological changes occur in structure and function (Goyer, 1971; Khalil-Manesh et al, 1992) . A single injection of lead nitrate significantly increased renal GSTs (PlanasBohne and Elizalde, 1992) , and acute administration of triethyl lead chloride induced GSTs in rat kidney but decreased hepatic GST levels (Daggett et al, 1997) . In addition, chronic administration of inorganic lead during development or acute exposure produced cell-type specific increases in particular /x, a or 77 isoforms in rat kidney Oberley et al, 1995) . Whether these changes in GSTs are a result of leadgenerated injury or serve as a protective adaptation remains unclear.
The current U.S. standard as established by the Occupational Safety and Health Administration requires removal from site of exposure when adult workplace blood lead levels exceed 50 /xg/dl, and the Centers for Disease Control has set a blood level of 10 n-g/dl as an advisory standard and level of action for children. Earlier studies from our laboratory in which we reported increases in GSTs were conducted using a very high dose of lead acetate (114 mg/kg) with concomitant highly elevated blood lead levels. In order to determine if GSTs are affected by more relevant environmental exposure amounts of lead, we examined the effects of acute exposure to lead acetate concentrations from 0.11 to 114 mg/kg (0.3 to 300 /nmol/kg) on renal GST expression in Sprague-Dawley male rats and correlated those findings with blood lead levels, loss of body weight, and histopathological changes in the proximal tubules of the kidney.
METHODS
Materials. Glutathione-agarose, 5-hexyl glutathione-agarose, lead acetate trihydrate, and all chemicals were purchased from Sigma Chemical Co. (St. Louis, MO). System Gold HPLC equipment was from Beckman Instruments (Palo Aha, CA) and C18 reverse-phase HPLC columns were from Vydac Co. (Hesperia, CA).
Animals. Male Sprague-Dawley rats (250-300 g) were raised in our AALAC-approved breeding facility and given free access to Harlan Teklad lab chow and water. Lead-treated animals were given three consecutive daily intraperitoneal injections of lead acetate in deionized water and were killed 24 h following the third injection. Control animals received three daily injections of physiological saline, and each dose was delivered in a volume of 1 ml/kg body wt. Each group contained a minimum of four animals. All data were expressed as means ± SE, and Student's r test was used for analysis of data.
Tissue preparation for HPLC. Animals were killed with CO 2 asphyxiation, and tissues were removed, homogenized in 4 volumes of 10 mM Tris-HC1, pH 7.8, 10 mM EDTA, 2 mM EGTA, 2 mM DTT with a polytron, and centrifuged at 100,000g for 30 min. The cytosols were stored at -80°C. Protein concentrations were measured by the method of Bradford (Bradford, 1976) using bovine 7-globulin as reference. GSTs were isolated from kidney cytosol by affinity chromatography on a mixed bed of GSH-agarose and S-hexyl glutathione-agarose (Hayes, 1988) .
GST activity assay. GST activity in cytosolic fractions was determined using a microplate reader to record change in absorbance at 340 nm with l-chloro-2,4-dinitrobenzene (CDNB) as substrate as described (Daggett et al, 1997) .
HPLC analysis. Separation of affinity-purified GSTs by reverse-phase HPLC was performed as described (Johnson et al, 1992) . Quantitation of the rat GST isoforms was based on the molar absorption coefficients (e) of each subunit (Johnson et al, 1992; Ostlund Farrants et al, 1987) and were expressed as picomoles GST subunit/milligram of cytosolic protein.
Electron microscopy. Kidney cortical region was sliced into 1-mm 2 squares, fixed in 20 volumes of 2% glutaraldehyde in 0.1 M NaP0 4 , pH 7.4, and processed for electron microscopy as described (Coursin et al, 1992; Muse et al, 1994) .
Lead analysis. Immediately after asphyxiation, blood was withdrawn from each animal by cardiac puncture, collected in 0.6-ml Multivette tubes containing potassium EDTA (Sarstedt, Germany), and stored at -80°C until assayed. Lead analysis was performed by the Wisconsin State Laboratory of Hygiene using a graphite furnace-atomic absorption spectrophotometer.
RESULTS
Male rats were injected ip daily for 3 consecutive days with 0.11, 0.38, 1.14, 3.8, 11.4, 38, or 114 mg/kg lead acetate (0.3 to 300 /xmol/kg), and body weights were recorded each day. Animals were killed 24 h after the third injection, and blood was collected from each animal by cardiac puncture for lead analysis at time of sacrifice. Changes in body weight are compared to blood lead levels in Fig. 1 . Control animals gained an average of 11.5 g over the 4-day protocol, and animals treated with 0.11, 0.38, 1.14, or 3.8 mg/kg also had the same weight gain as controls, whereas weight loss was observed at a dose of 11.4 mg/kg and escalated with increasing dose. No detectable lead was found in the blood of controls, but a blood lead level of 1.7 ± 2.9 /u-g/dl was observed at the lowest dose (0.11 mg/kg) and increased to 132 ± 18 /xg/dl (38 mg/kg). The highest dose (114 mg/kg) was above the limits of detection (>160 jxg/dl)-B otn sets °f data exhibited a similar pattern of nonlinear plots with significant changes commencing at a dose of 11.4 mg/kg for the onset of loss in body weight (-6.2 ± 2.4g) and for blood lead levels (20.3 ± 1.45 /j,g/dl) beginning at a dose of 0.38 mg/kg. Cytosolic fractions were prepared and assayed for GST activity using CDNB as substrate, and changes in GST activity were compared to the respective blood lead levels (Fig. 2) . GST activity greater than control was detected at a dose of 1.14 mg/kg and increased at a linear rate until reaching the maximal response at a dose of 38 mg/kg. This increase in activity paralleled the changes in blood lead levels. When the linear correlation coefficents (r) for the data sets of dose, weight loss, blood lead levels, and total GST activity were compared with respect to each other (Table 1) , there was a very high positive relationship between all four assay parameters as evidenced by a correlation coefficient for each comparison >0.87. Because no blood lead level from the highest dose (114 mg/kg) was obtainable, all data set comparisons were made from doses of 0 (control) through 38 mg/kg.
Sections from renal cortex were fixed in 2.5% glutaraldehyde and prepared for electron microscopy. To provide semiquantitation of tubular injury, randomly selected proximal tu- Correlation of total GST activity with blood lead levels. Cytosols were prepared from the kidneys of control and lead-treated animals and assayed for GST activity. GST activity expressed as nmoles CDNB conjugated/min mg and blood lead content expressed as /xg/dl were plotted against the log value of the lead dose. Results were expressed as means ± SE. Significantly different from control values (Student's t test): a, p < 0.001; b, p < 0.01, c): p < 0.05. The asterisk (*) signifies a blood lead value above the limits of detection.
bule profiles from each group were photographed and the number of cellular casts, a diagnostic indicator of renal tubule damage, was quantitated. Proximal tubules from animals treated with lead acetate at doses of 0.11 mg/kg (Fig. 3a) , 0.38 mg/kg (Fig. 3b) , and 1.14 mg/kg (Fig. 3c ) exhibited no structural changes in cytoplasmic contents, mitochondria, nuclei, and heterochromatin compared to control proximal tubules (data not shown), whereas proximal tubules from animals treated with 3.8 mg/kg (Fig. 3d) had occasional mitotic cells. Animals treated with 0.11 mg/kg showed no cellular casts. Doses of 0.38, 1.14, and 3.8 mg/kg showed one cellular cast/ profile (approximately 11% of tubules). Doses of 11.4 mg/kg (Fig. 3e) and 38 mg/kg (Fig. 3f) both showed prominent injury indicated by the presence of six cellular casts/profile (approximately 67%). No lead inclusion bodies or interstitial fibrosis was observed in animals treated with a lead dose of ^38 mg/kg. Kidney cytosolic GSTs from were isolated by affinity chromatography and then resolved and quantified by reverse-phase HPLC. The ratio of the sum of the individual GST isoform protein and the total GST activity remained constant throughout the experiment indicating that there was no enzyme inactivation caused by lead (data not shown). Changes in /x-class GSTs are shown in Fig. 4a . rGSTM3 and rGSTM5 showed marginal increases only at the highest dose (114 mg/kg), whereas rGSTM2 showed a small change at a dose of 38 mg/kg and a modest increase at the highest dose. The greatest increase was seen in rGSTMl, which was significantly elevated over control at a dose of 3.8 mg/kg and rose to a value that was 450% over control at the highest dose. A significant increase in rGSTPl was detected at a lead dose of as low as 1.14 mg/kg (Fig. 4b ). rGSTPl displayed a very similar rate of increase to rGSTMl, culminating with a maximum increase of 450% above control at the highest dose. The effects of lead on a-class GSTs are shown in Fig. 4c . Minimal changes in rGSTA4 were detected only at the highest dose, and rGSTA2 was increased slightly at doses of 38 and 114 mg/kg. rGSTAl and rGSTA3 were both elevated at a dose of 1.14 mg/kg and reached a maximum of 275% over control at the highest dose, although the rates of increase were different for the two isoforms.
DISCUSSION
This study determined the effect of acute exposure to increasing doses of inorganic lead in rat kidney and correlated the changes in renal GSTs with blood lead levels and histopathological occurrence. Earlier studies from our laboratory had demonstrated that exposure to lead in drinking water from conception until 7 weeks of age caused kidney damage characterized by interstitial fibrosis, cellular pleomorphism, and tubular atrophy and calcification (Oberley et ah, 1995) . Substantial increases in rGSTPl, rGSTMl, and rGSTA3 and modest increases in rGSTAl, rGSTA2, and rGSTM2 were also observed (Moser et ah, 1995) . In that same study, another set of animals were dosed for three consecutive days with 114 mg/kg lead acetate, and similar increases in specific GST isoforms were detected. The LD50 for intraperitoneal exposure to lead acetate in rats is 150 mg/kg (Masci and Bongarzone, 1995) . Therefore, this study was undertaken to determine if changes in GSTs occurred at a more physiologically relevant level of exposure.
A blood lead level of 60 jitg/dl is the apparent threshold for tubule damage in chronic exposure for humans and animals (Loghman-Adham, 1998), and OSHA standards require immediate removal from exposure when adult workplace blood lead levels exceed 50 /n.g/dl. Our findings show that control animals and animals dosed with <3.8 mg/kg lead acetate gained weight over the 72-h period. In contrast, animals injected with doses > 11 mg/kg displayed a loss in body weight, and this change was in parallel with increases in blood lead levels as well as dose. Furthermore, changes in total GST activity exhibited an analogous rate of increase as did blood lead and weight loss. Electron microscopy of proximal tubules of lead-treated animals. Proximal tubules from rats given a dose of (a) 0.11 mg/kg lead acetate showed no significant morphological changes compared to control proximal tubules. Nuclei (N) were round and regular with normal amounts of heterochromatin. The cytoplasm showed numerous mitochondria (M), protein droplets (P). and lipid droplets (L). The cell surface showed long miciuviili (MV). Doses of 0.38 mg/kg (b) and 1.14 mg/kg (c) showed no significant morphological changes from control. Proximal tubules from a dose of 3.8 mg/kg (d) showed evidence of cellular injury with occasional mitotic cells (arrow). Cellular casts were rare. Doses of 11.4 mg/kg (e) and 38 mg/kg (f) showed significant cellular injury as indicated by the presence of numerous cellular casts (arrows).
These four parameters are highly correlated with each other as demonstrated by their correlation coefficients (Table 1) . A study of nephropathy in children caused by acute lead poisoning suggested a dose-dependent relationship between blood lead levels and renal symptoms (Castellino et ai, 1995) . Our results are the first report that increases in GSTs are closely linked to lead exposure and the resultant tissue damage in a dose-specific manner.
The increases in specific GST isoforms precede the cellular and physical changes, thereby providing an extremely sensitive tissue biomarker of lead exposure. Deleterious effects of acute exposure to high amounts of lead in kidney are indicated by the appearance of lead inclusion bodies located in the nuclei of proximal tubular cells, mitochondrial swelling indicative of respiratory dysfunction, and tubular defects demonstrated by aminoaciduria, glycosuria, and hypophosphatemia (Goyer, 1971) . Our laboratory has confirmed these observations and has reported that after three daily ip injections of lead acetate at 114 mg/kg, mitoses, tubular disarray, nuclear inclusion bodies, and cellular injury were seen (Daggett et al, 1998; Oberley et al, 1995) . In the present study, morphological changes were first detected at a lead dose of 3.8 mg/kg and preceded the onset of weight loss. In addition, the evidence of cellular damage, as indicated by the presence of cellular casts, mitoses, and tubule disarray, increased with dose and also paralleled the increases of blood lead and weight loss. However, changes in total GST activity and a specific increase in the rGSTPl isoform were observed at even a lower dose, 1.14 mg/kg, before morphological changes had occurred.
The regulation of GST induction is complex. In this study, protein levels for rGSTA4, rGSTM3, and rGSTM5 were relatively unchanged after any lead treatment, modest increases were detected for rGSTA2 and rGSTM2, and large increases were observed for rGSTAl, rGSTA3, rGSTM 1, and rGSTPl. Recent studies from our laboratory have shown that this increase was due to increased transcriptional rates (Daggett et al., 1997 (Daggett et al., , 1998 . Extensive studies on the rat GSTP1 gene indicate that there are multiple enhancer and silencer elements in the 5'-flanking region (Imagawa et al, 1991; Hayes and Pulford, 1995) . Suzuki et al. demonstrated that the lead-activated induction of rat GSTP is mediated through the GPEI enhancer (Suzuki et al, 1996) , and our findings confirmed that rGSTPl increased 450% in response to low amounts of lead. Whether this lead-specific control acts directly upon those c/s-elements or is involved via a second messenger or signaling cascade is unknown. Further study is needed to understand the transcriptional control mechanisms for the individual GST isoforms and, in particular, the specific role that lead plays in the expression of this important family of detoxification enzymes.
